Related Experiment Video
Updated: Jan 11, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
23.0K
Exploring Ayurveda's Potential in Parkinson's Disease: A Comprehensive Narrative.
Umesh Chikkanna1, Shivakumar Venkatram1, Bharath Holla1
1Department of Integrative Medicine, National Institute of Mental Health and Neurosciences, Bengaluru, IND.
Cureus
|November 10, 2025
Summary
Ayurvedic approaches, particularly Mucuna pruriens, show promise in managing Parkinson's Disease (PD) motor symptoms. Further research with classical texts and objective measures is needed for robust evidence.
Area of Science:
- Ayurvedic Medicine
- Neurodegenerative Disorders
- Clinical Research
Background:
- Parkinson's Disease (PD) shares similarities with the Ayurvedic concept of kampavāta.
- Ayurveda offers a unique framework for understanding and managing PD.
Purpose of the Study:
- To review Ayurvedic understanding of PD.
- To evaluate clinical literature on Ayurvedic interventions for PD management.
Main Methods:
- Searched classical Ayurvedic texts and databases (PubMed, Google Scholar, AYUSH).
- Identified clinical trials using Ayurvedic medicine for PD (2000-2020).
- Screened 126 studies, including 7 for analysis.
Main Results:
- Six studies indicated benefits from Mucuna pruriens (M. pruriens) for PD.
- One study highlighted bio-cleansing combined with M. pruriens.
- M. pruriens improved motor symptoms and extended the ON state with a favorable side effect profile.
Conclusions:
- Mucuna pruriens demonstrates potential in ameliorating Parkinson's Disease motor symptoms.
- Future research should align with classical texts, use objective measures, and include longer follow-ups.
Related Concept Videos
01:24Parkinson's Disease: Treatment
954
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
954
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:22Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
01:37Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:20Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K